Lumida
/RCUS
⌘K
Arcus Biosciences Inc

Arcus Biosciences Inc

RCUS
$24.59USD-5.97%-1.56 today

MARKET CAP

3.1B

P/E (TTM)

FWD P/E

DAY RANGE

$24 – $27

52W RANGE

$11
$32

AI Summary

Stalk
Sell NowMedium

RCUS is in Stage 3 distribution and has triggered a support failure pattern with price closing sharply below key intra-month support on high volume, signaling committed selling. Short-term momentum is negative with price rejected at the 9/20/50 EMAs and approaching the 200-day SMA, while the long-term uptrend remains intact above the rising 200-day SMA. The medium-term bias is bearish, and negative short-term conditions favor immediate downside participation. A decisive reclaim of the broken support band and EMAs would invalidate the bearish posture.

  • Management forecasts $5–10B peak sales for casdatifan in RCC market
  • $775M cash as of Q2 2026 funds operations into H2 2028 amid R&D spending cuts
  • Q2 2026 net loss of $91M and full-year revenue guidance of $65–75M underscore weak profitability
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$383.0M$112.0M$117.0M$258.0M$247.0M
YoY %+391.0%-70.8%+4.5%+120.5%-4.3%
P / Sales7.8x13.0x12.4x5.2x10.4x
EV / Sales9.4x17.3x16.8x7.2x11.5x
Gross Profit, Adj.$383.0M$112.0M$117.0M$258.0M$247.0M
YoY %+391.0%-70.8%+4.5%+120.5%-4.3%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit9.4x17.3x16.8x7.2x11.5x
EBITDA, Adj.$61.0M$-274.0M$-332.0M$-300.0M$-376.0M
YoY %+150.8%-549.2%-21.2%+9.6%-25.3%
Margin %15.9%-244.6%-283.8%-116.3%-152.2%
EV / EBITDA59.0x-7.1x-5.9x-6.2x-7.6x
EBIT$54.0M$-280.0M$-340.0M$-330.0M$-386.0M
YoY %+143.5%-618.5%-21.4%+2.9%-17.0%
Margin %14.1%-250.0%-290.6%-127.9%-156.3%
EV / EBIT66.6x-6.9x-5.8x-5.6x-7.4x
Net Income$53.0M$-267.0M$-307.0M$-283.0M$-353.0M
YoY %+143.1%-603.8%-15.0%+7.8%-24.7%
Net Margin13.8%-238.4%-262.4%-109.7%-142.9%
EPS (GAAP)$0.71-$3.71-$4.15-$3.14-$3.29
YoY %+131.7%-622.5%-11.9%+24.3%-4.8%